Longevity-oriented research increasingly references the "hallmarks of aging" framework (Lopez-Otin et al., 2013) and investigates compound combinations that engage more than one hallmark in parallel. The rationale for combining compounds is mechanistic rather than person-specific. This article summarises the pathways most commonly mapped to peptide combinations in the published literature. It is not a protocol, not a recommendation and not health advice for any person.
Hallmarks Researchers Map onto Compound Combinations
- NAD+ decline: Investigated with NMN and NR in published metabolite and pharmacokinetic studies
- Mitochondrial dysfunction: Investigated with SS-31 (elamipretide) and MOTS-c
- Cellular senescence: Investigated with senolytic candidates such as fisetin and FOXO4-DRI in preclinical models
- Impaired autophagy: Referenced in spermidine literature
- Telomere attrition: Referenced in epithalon and telomerase-activation literature
- Loss of extracellular matrix integrity: Referenced in GHK-Cu transcriptomics
Why Combinations Rather Than Single Compounds
Aging is reported in the literature as a multi-pathway process. Single- pathway interventions in animal models tend to show pathway-specific effects without addressing parallel mechanisms. Researchers therefore examine combinations that engage multiple hallmarks simultaneously, either in animal lifespan studies or in defined biomarker endpoints.
Commonly Referenced Pairings
NAD+ Pathway with Mitochondrial Support
NMN/NR have been characterised in published work as NAD+ precursors restoring metabolite levels that decline with age. MOTS-c and SS-31 have been characterised as mitochondrial-targeted peptides. Researchers combine them in metabolic and exercise-tolerance models to investigate whether substrate restoration and mitochondrial function changes are additive.
Epithalon with GHK-Cu
Epithalon has been studied in Russian gerontology literature for telomerase and pineal-axis endpoints. GHK-Cu has been characterised transcriptomically for extracellular matrix and DNA-repair gene expression. The pairing recurs in regenerative-research literature as a multi-pathway probe.
Senolytic Candidates with Anti-Inflammatory Peptides
Senolytic compounds such as fisetin have been investigated in preclinical models for clearance of senescent cells, which are associated with sustained inflammatory secretion (SASP). Pairing with peptides characterised for inflammatory pathway modulation is investigated in published model systems.
Open Research Questions
- Whether reported animal lifespan extension translates to defined human biomarkers in any randomised trial
- Whether intermittent dosing referenced in senolytic literature is the appropriate model for combined protocols
- How combined exposure influences long-term safety endpoints in regulated clinical research
Key References
- Lopez-Otin, C. et al. (2013). "The hallmarks of aging." Cell, 153(6), 1194-1217.
- Yoshino, J. et al. (2018). "NAD+ intermediates: the biology and therapeutic potential of NMN and NR." Cell Metabolism, 27(3), 513-528.
- Pickart, L. and Margolina, A. (2018). "Regenerative and protective actions of the GHK-Cu peptide." International Journal of Molecular Sciences, 19(7), 1987.
- Yousefzadeh, M.J. et al. (2018). "Fisetin is a senotherapeutic that extends health and lifespan." EBioMedicine, 36, 18-28.